Results 221 to 230 of about 1,221,083 (383)

National Mortality Databases to Assess Disease Burden in Systemic Autoimmune Diseases: A Valuable Resource, But with Limitations

open access: yesArthritis &Rheumatology, Accepted Article.
Disease‐specific mortality statistics are useful measures of disease burden. Population‐based studies from a few United States counties have reported mortality in systemic autoimmune diseases (SAID). However, due to substantial differences in the population structure of these counties as well as relatively small numbers of SAID deaths in these counties,
Ram Raj Singh
wiley   +1 more source

Therapeutic drug monitoring education: The current state

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims To evaluate available information on therapeutic drug monitoring (TDM) education programmes and their implementation across different countries. Methods The study was performed in two phases. First, a scoping review of scientific literature on available education programmes was performed.
Guenka Petrova   +10 more
wiley   +1 more source

AZD0449, an inhaled JAK1 inhibitor, in healthy participants and patients with mild asthma

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Inhaled corticosteroids (ICS) plus bronchodilator are recommended for the treatment of asthma. Targeting the JAK1‐dependent pathway may be an alternative for asthma management in patients with incomplete response to ICS. The aim of this study was to investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AZD0449, a
Anna Lundahl   +11 more
wiley   +1 more source

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy